問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳怡君

Recruiting

List

89Cases

2019-11-01 - 2022-12-31

Phase II

An Open Label Randomized Phase 2 Trial of Amcenestrant (SAR439859), Versus Endocrine Monotherapy as Per Physician's Choice in Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies

  • Condition/Disease

    Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies

  • Test Drug

    SAR439859 SAR439859

Participate Sites
5Sites

Recruiting5Sites

2022-03-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-12-15 - 2028-11-13

Phase III

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07220060 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Participants Over 18 Years of Age with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

  • Condition/Disease

    Advanced or Metastatic Breast Cancer

  • Test Drug

    PF-07220060 Fulvestrant Everolimus Exemestane

Participate Sites
7Sites

Recruiting7Sites

2020-05-01 - 2025-06-30

Phase III

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor

  • Condition/Disease

    advanced or metastatic breast cancer

  • Test Drug

    Capivasertib

Participate Sites
9Sites

Recruiting9Sites

2021-12-01 - 2022-12-12

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-08-01 - 2036-12-31

Phase III

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

  • Condition/Disease

    Breast Cancer, Early Breast Cancer

  • Test Drug

    Camizestrant (AZD9833)

Participate Sites
8Sites

Recruiting8Sites

2022-02-01 - 2027-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-11-01 - 2026-12-31

Phase III

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    Lasofoxifene

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2026-12-31

Phase II

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer’s Disease

  • Condition/Disease

    Mild Alzheimer Disease

  • Test Drug

    EX039

Participate Sites
4Sites

Recruiting4Sites

2020-08-01 - 2022-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB